

Print ISSN: 2656-0097 | Online ISSN: 0975-1491

Vol 15, Issue 1 2023

Case Study

CASE SERIES OF EMERGING NOSOCOMIAL MULTIPLE DRUG RESISTANT PATHOGEN PROVIDENCIA RETTGERI CAUSING URINARY TRACT INFECTION

MAYURI MAHAJAN¹, PRASANNA S.^{2*}, NIKUNJA KUMAR DAS³, NIKHIL MAHAJAN⁴

¹Department of Microbiology and Pathology, Dr Hedgewar Hospital and Research Centre, Akola, ^{2*}Department of Microbiology, Shri Sathya Sai Medical College and Research Institute, Sri Balaji Vidyapeeth (Deemed to be University), Chengalpattu, Tamil Nadu 603108, ³Department of Microbiology, D. Y Patil Medical College Hospital and Research center, DY Patil Vidyapeeth, Pimpri, Pune, ⁴Clinical Consultant and Head, Pediatrics and neonatology, Dr Hedgewar Hospital and Research Centre, Akola *Email: dr mayurikulkarni@rediffmail.com

Received: 03 Nov 2022, Revised and Accepted: 30 Nov 2022

ABSTRACT

We report Case Series of Emerging Nosocomial Multiple Drug Resistant Pathogen *Providencia rettgeri* causing Urinary Tract Infections. The most common cause of catheter-associated urinary tract infections (CAUTI), especially with long-term indwelling urinary catheters in elders, are *P. rettgeri* and *P. stuartii*. We are reporting 4 cases of UTI, which are hospital-acquired and CAUTI. These cases are admitted to MICU for treatment purposes and later develop fever spikes after a few days and are evaluated and urine culture showed multi-drug-resistant *Providencia rettgeri* by VITEK. The empirical therapy was discontinued, managed with fosfomycin, and discharged later with follow-up. The various reports showed *P. rettgeri* is susceptible for amikacin, gentamicin, tobramycin and ciprofloxacin. In our case series, we isolated multi-drug-resistant strains of *P. rettgeri* that showed resistance to piperacillin-tazobactam, cefuroxime, ceftriaxone, cefepime, ertapenem, imipenem, meropenem, gentamicin, tobramycin, ciprofloxacin, tigecycline, amikacin, colistin and sensitive only to fosfomycin. The significance of *P. rettgeri* in association with catheter-seciated bloodstream infections (CRBSI) and catheter-associated urinary tract infections. The proper selection of empirical antimicrobials, antibiotic sensitivity testing, avoiding misuse of antibiotics and implementing proper drug holiday and local antibiotic policy are considered appropriate combination protocol for managing emerging multi-drug-resistant nosocomial *Providencia rettgeri* strains.

Keywords: Emerging, Nosocomial pathogens, Multi-drug-resistant, Providencia rettgeri

© 2023 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) DOI: https://dx.doi.org/10.22159/ijpps.2023v15i1.46740. Journal homepage: https://innovareacademics.in/journals/index.php/ijpps.

INTRODUCTION

Rettgeri in 1909 discovered *Providencia rettgeri* in chickens from a cholera like epidemic [1]. *Providencia stuartii, P. rettgeri, P. alcalifaciens, P. rustigianii,* and *P. heimbachae* are urease-producing gram-negative bacillus belong to the Providencia genera under the Enterobacteriaceae family. *P. rettgeri* and *P. stuartii* are opportunistic pathogens in residents and hospitalized patients, commonly found in soil, water, and animal reservoirs. The most common cause of catheter-associated urinary tract infections (CAUTI), especially with long-term indwelling urinary catheters in elders, are *P. rettgeri* and *P. stuartii*. Usually, the mortality rate will be high among the elderly population when Providencia genera are associated with urinary tract infections (UTI) or bacteraemia. *Providencia rettgeri* most commonly associated with long-term indwelling urinary catheters and multi-drug-resistant isolates [2-4].

The essential virulence factors for Proteus species, Morganella species and Providencia species are bacterial urease; type III fimbriae play a pivotal role in the formation of urinary tract stones, obstruction of long-term urinary catheters and complicating acute pyelonephritis [5, 6]. Even though the purple urine bag syndrome is a rare and asymptomatic condition if present, physicians should consider indoxyl sulphatase or phosphatase producing *P. stuartii* or *P. rettgeri* [7]. This case series is reported to highlight the importance of this emerging nosocomial pathogen *Providencia rettgeri* and to understand in depth about prevention and management because of multi-drug resistance.

Case descriptions

Case 1

A 46-year-old male presented to the emergency department with chest pain, breathlessness on walking, and drowsiness since morning. The patient was a known hypertensive and not a known diabetic. On clinical examination and further investigation, the patient was diagnosed with ischemic heart disease, Post MI pericarditis, type 2 diabetes mellitus, and thrombolysed with retiplase, and the ejection fraction was 42%. He was admitted to the Intensive care unit (ICU), and other routine investigations were done. The nasopharyngeal swab was sent for RT-PCR, and turned out to be COVID-19 negative. All blood investigations were within normal range except blood glucose, and cholesterol and the patient was catheterized by Foley's catheter. The patient was given insulin and empirical antibiotics because of fever spikes after three days. The blood and urine sample was sent for culture and sensitivity; a Gram stain of urine showed numerous pus cells with gram-negative bacilli. Initially, the patient was managed with a piperacillin and tazobactum combination and completes monitoring.

Case 2

A 78-year-old male presented to the general medicine department with hypoglycaemia and sudden drowsiness for 1 w. The patient was a known hypertensive and diabetic and had no history of stroke or ischemic heart disease. On clinical examination and further investigation, the patient was diagnosed as right side hemi paresis with type 2 diabetes mellitus. He was admitted to ICU, other routine investigations were done, and the patient was catheterised. The nasopharyngeal swab was sent for RT-PCR, and turned out to be COVID-19 negative. All blood investigations were within normal range except for increased WBC count, blood glucose and serum electrolytes. The patient was given insulin and empirical antibiotics because of fever spikes with chills and rigor after a few days. The blood and urine sample was sent for culture and sensitivity; Gram stain of urine showed numerous pus cells with gram-negative bacilli. Initially, a patient was managed with a ceftazidime sulbactam combination and completed monitoring.

Case 3 and 4

There were two cases of chronic liver disease with a known history of diabetes and hypertension admitted to the Medical ICU. All other routine investigations were done, including liver function test. The nasopharyngeal swab was sent for RT-PCR, and turned out to be COVID-19 negative. All blood investigations were within normal range except for increased WBC count, blood glucose, and abnormal liver function tests and the patient was catheterized. The patient was given insulin and empirical antibiotics because of fever spikes after a few days of hospitalization.

The management of all cases

The blood and catheter urine was cultured in blood, chocolate, MacConkey and Sabouraud dextrose agar with aseptic precautions. The urine culture was processed in VITEK and identified as multidrug-resistant *Providencia rettgeri* sensitive only to fosfomycin (fig. 1 and fig. 2). All urine culture growth was re-isolated and correlated clinically also. The blood culture was shown no growth. Fosfomycin 3 grams (1 sachet) orally once as a single dose was given along with supplements because all other antimicrobials turned out as resistant (multi-drug resistant *Providencia rettgeri*) by VITEK. The patient's vital parameters were stable and discharged later. Further follow-up was ensured about the completion of treatment and improvement based on clinical findings and negative culture reports.



Fig. 1: Colonies of *Providencia rettgeri* in blood agar (Left side)-non hemolytic semi-translucent colonies; Mac conkey agar (right side)non-lactose fermenting semi-translucent colonies

				Physician		Organism Quantity:				Physician	and Pin
Organism Quantity: modern selected Organism : Provi up Infection Site:	ne idencia rettgeri	-			-	Selected Organism : Provide DP Infection Site Source: URINE	ncia retigeni 🤞	-			2nd fis
Source: URINE		1		0	offected: Oct 21, 2022	Source: UKINE	-				denset Ogg, 2
						Connetti					
Comments:						Identification Information		Analysis Time:	4.07 hoses	Statust	Final
	-			VICE		Selected Organism		95% Probability Biomambers	Providencia retigeri 2007110200040411		
Susceptibility Informat	ion Analysis	Time: 18.03-boars		Status:		ID Analysis Messages		10	00000		
Antimicrobial	MIC	Interpretation		MIC	Interpretation	Susceptibility Information	Analysis T	ime: 10.90 hours		Status	Final
Piperacillin Tazobactam	>= 128	R	Ciproflexacin	>+4	R	Antimicrobial	MIC	Interpretation	Antimicrobial	MIC	Interpretati
Ceftaridime	>= 64	R	Levofloxacin	>= 8	R	Approxicillin Clavulanic Acid	and	interpretation	Amilarin	-64	R
Celoperazone Sulbactam	>= 64	R	Minocycline	>= 32	R	Piperscillin Tanibactan	>> 128	R	Gentanticin	-16*	ĸ
Celepime	>= 32	R	Tigecycline	>= 8	-	Cetaronine	- 64	R	Ciprofloxacin	20.4	R
Aztreonam	>= 64	R	Fosfomycin Urine	32	5	Cefuroxime Axetil Cefmaxone	>= 64 >> 64	8	Tigecycline Fosfomycie	>+8	R
Iniperem	>= 16	R	Other	32	6 5	Cofoperations/Sulbactam	- 64	R	Evine .	64	-
Meropenem		R	Colistin	32		Celepime	>= 32	R	Other	01	
Amikacia	>= 64	R				Ertaponom	3118	R	Colistie	16	R
kentamicin	>= 16*	K	Trimethoprim/ Sulfamethoxazole	>= 320	×	Imiponero	16	R	Trimethopein/ Sulfamethosazole	>= 320	K
											-
- AXS modified **- User mode	ified					Meropenem	0=16	R			
	fied					Meropenens		R			
AES Findings	ified	metion Microbiology	Chart Report Prior		2022 1.05:15 PM IST 4 ID: 4070115102022	ALS modified the User modified			у слаткерот Р	inted October 29, 1	1 1022 11-28-59 AM
aniste Quantity: moderate	onsistent with co	-	Chart Report Prize		2022 1:05:15 PM IST II ID: 4070115102022	** XIS malified *** User malified AES Findings Confidence: Con			y Char Report		1 2022 11-28-59 AM
AES Findings astidesce: C antar Quantity: moderate ceted Organism: Providen electron Site:	onsistent with co	-	Chart Report Prior	Patien		** XIS malified *** User malified AES Findings Confidence: Con	instent with cor		g Char Report	1	
NES Findings osfidesce: C	onsistent with co	-	Chart Report Prior	Patien Physician:		*- 435 modified **- Use modified A.S. Findings Confidence: Confidence: Confidence: Common Control: Co	instent with cor		g chur kepon – Pr	l Physica	
AES Findings astidesce: C antar Quantity: moderate ceted Organism: Providen electron Site:	onsistent with co	-	Chart Report Prior	Patien Physician:	n ID: 4070115102022	** AD waited **- Lee waited AES Findings Canfateure Caloriter Appen Caloriter Strend Organize Previde BP Infection Ste	instent with cor		g caar kepar . Pr	l Physica	Veices II): 61 7610
AES Findings antidence: [C antidence: [C ant	onsistent with co	Macrobiology	Chart Report Prior	Patien Physician:	HD: 4070115102022	 Alto melled the Law medified ALES Findings Confidence Confidence Confidenc	interet with cor	rection Metropology		l Physica	ellected: Oct 26,
AES Findings antidence: 0 antidence: 0 antid	onsistent with co	Microbiology		Patien Physician Co Status:	HD: 4070115102022	A De andited The Use multitle Argenting Continue Contin Continue Continue Continue Continue Contin	n Analysia 1 MIC	vection	Antimicrobial	Terreration of the second seco	ellected: Oct 26,
ALES Findings antidence: or Opposity - moderate or Opposity - moderate or Opposite - Providen intrins Sag. Provident intrins - Provident intrins -	onsistent with co	Microbiology e: 14.13 hours Interpretation	Antimicrobial	Patien Physician Co Status: MIC	ID: 4070115102022 IBected: Oct 15, 2022 Final Interpretation	A De analited The Van examine Are Erstandings Constance	interet with cor	rection Macrosomo		Physical Co Status:	ellected: Oct 26,
LES Findings antidence: C antidence: C antid	onsistent with co	Microbiology e: 14.13.bours Interpretation	Antimicrobial	Patien Physician Co States: MIC >= 16	HD: 4070115103022 Breted: Oct 15, 2022 Final Interpretation R	¹ a Use and the 's provided <u>ASS Finders</u> <u>Cardiform</u> <u>Construction</u> <u>Sector Construction</u> <u>Sector Construction</u> <u>Sector Construction</u> <u>Sector Construction</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Co</u>	n Analysia 1 MIC	rection	Antimicrobial	Terreration of the second seco	Final
SES Findings antidence: C antidence: C antidence: C antidence: C antidence: C antidence: C antidence: C antimicrobial c antimicrobial	onsistent with co	Microbiology e: 14.13 hours Interpretation	Antimicrobial Edvançin zeoforacin	Patien Physician Co Status: MIC >= 16 >= 8	Retref: Ort 15, 2022 Final Final Retref: Retre	¹ A De anality The Very anality A <u>CF Endinge</u> Candom: (non- blance Cannon) (Parallel Candom) (Parallel Candom)	internt with cor index retigers of <u>MIC</u> ≈ 123 $> \sim 64$	Treetion Marconnect	Antimicrobial	1 Physicia C Status: Status: Statistica Stat	rises ID- 61 Xata directed: Oct 26, Final Interpretat R R R
LES Findings antidence: (c) antidence: (c) antidenc	consistent with co	Microbiology e: 14.13 hours Interpretation R 1	Antimicrobial Gitrançia zeofinacia	Patien Physician. Co Status: MIC >= 16 >= 8 >= 16	HID: 4070115103022 Rected: Oct 15, 2822 Final Interpretation R R R R R R R R R R R R	¹ all sealing the large and the large sealing the large seating the large seati	n Analysis 1 MIC	Time: 11.0) hore Reserved	Antimicrobial Ciprólosacio Levedosacio Minocycline Tipocycline	Status: MIC 2 >= 8	Final
LES Findings antidence: (c) antidence: (c) antidenc	onsistent with co	Microbiology e: 14.13 hours Interpretation R 1	Antimicrobial Edvançin zeoforacin	Patient Physician Co Status: MIC >> 16 >> 16 >> 16 >> 16 >> 16	HID: 4070115103022 Rected: Oct 15, 2022 Final Interpretation R R R R R R R R R R R R R R R R R R R	¹ A De anality The Very working A SE Findings Candidance (Control of Control Payment Control of Control Payment Control of Control Patholics Sector Patholics Sector Secret Children (Control Paymenting Todayana) Catanatian Cata	n Analysis 1 MIC 	Time: 18.0) hours	Antimicrobial Ciprifonacio Lecofonacio Minoceline Tigocytine Fostonycio	T Physica C States:	Final Recepted: Oct 26, Final Recepted R R R R R
ES Findings antidense: [C antidense: [C antidens	consistent with co	Microbiology e: 14.13 hours Interpretation R R	Antimicrobial Gitrançia zeofinacia	Patien Physician. Co Status: MIC >= 16 >= 8 >= 16	HID: 4070115103022 Rected: Oct 15, 2822 Final Interpretation R R R R R R R R R R R R	 24 Standard The Language 24 ST Finding: Contrast: Contrast:<td>n Analysia rettgeri MiC</td><td>Time: 11.0) hore Reserved</td><td>Antimicrobial Ciperboacio Levoltoracio Minecycline Tigorycline Feodonycio Utine</td><td>T Physical C Status:</td><td>rises ID- 61 2518 effected: Oct 26, Final Interpretat R R R R S</td>	n Analysia rettgeri MiC	Time: 11.0) hore Reserved	Antimicrobial Ciperboacio Levoltoracio Minecycline Tigorycline Feodonycio Utine	T Physical C Status:	rises ID- 61 2518 effected: Oct 26, Final Interpretat R R R R S
ALSS Findings	cia rettgeri Matysis, Tim MIC >= 64	e: 14.13 hours	Antimicrobial form;cin confracin broggdine fors;cline	Patient Physician Co Status: MIC >> 16 >> 16 >> 16 >> 16 >> 16	HID: 4070115103022 Rected: Oct 15, 2022 Final Interpretation R R R R R R R R R R R R R R R R R R R	¹ Al De andial Pho Lee module ATE Finding Candidance (Control of Control Science) (Control of Control Science) (Control of Control Science) (Control of Control Control of Control of Control of Control of Control of Control Control of Control of Con	n Analysia Mice rettgeri Mice	Time: 11.83) hour	Antimicrobial Cprofosacia Levelosacia Minoycline Tegoyyline Feedonycia Utine Other	1 Physicia CO States: States: 	Final Rected: Oct 26, Final R. R. R. R. R. R. R. R. S. S.
LES Findings antideer. (c antideer. (c antideer. (c antideer. (c) antideer. (c) antide	consistent with co cia rettgeri MIC >= 64 >= 64 >= 16 >= 32	Microbiology et 14.13 hours Interpretation R R R R R	Antimicrobial Ideamicin avofinacin Despyceline Telepised Weensphericel States	Patient Physician. Co States: MIC >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16	Reted: Oct 15, 2022 Final Final Reted: R R R R R R R R R R R R R R R R R R R	Adds Charlenge Constant Adds Charlenge Constant Adds Charlenge Constant Constant Constant Constant Constant Constant Constant Constant Constant Constant	n Anatysis 7 MIC >= 16 32 >= 16 32 >= 16 32 >= 16	rection Anterconnect Fine: 18.03 hour R R R R R R R R R R R R	Astimicrobial Ciperfloracio Leventoucio Minocycline Teodonycio Urine Other Collario Collario	T Physica O Status: → 8 → 22 → 8 → 22 → 10 → 12 → 10	rises ID- 61 2518 effected: Oct 26, Final Interpretat R R R R S
ALSS Findings	Analysis Tim MIC >= 64 >= 16	Microbiology et 14.13 hours Interpretation R R R R R	Antimicrobial fobrançcia zerofnacia Denyçeline Téxesçidee Microaphenicol	Patient Physician. Co States: MIC >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16	Reted: Oct 15, 2022 Final Final Reted: R R R R R R R R R R R R R R R R R R R	¹ Al De andial Pho Lee module ATE Finding Candidance (Control of Control Science) (Control of Control Science) (Control of Control Science) (Control of Control Control of Control of Control of Control of Control of Control Control of Control of Con	n Analysia Mice rettgeri Mice	Time: 11.83) hours	Antimicrobial Cpendonacio Levelonacio Microyaline Teposycime Feodomycine Colorine Colorine Colorine Trinechopriori	1 Physicia CO States: States: 	Final Rected: Oct 26, Final R. R. R. R. R. R. R. R. S. S.
LES Findings antidence: C antidence: C antid	onsistent with co	Microbiology e: 14.13.bours Interpretation	Antimicrobial	Patien Physician Co States: MIC >= 16	HD: 4070115103022 Breted: Oct 15, 2022 Final Interpretation R	¹ a Use and the 's provided <u>ASS Finders</u> <u>Cardiform</u> <u>Construction</u> <u>Sector Construction</u> <u>Sector Construction</u> <u>Sector Construction</u> <u>Sector Construction</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Conserve</u> <u>Co</u>	n Analysia T MIC 32 32	Treffice Norrobony	Antimicrobial Cipuflosacio Levelosacio	Status: MIC 2 >= 8	Final
ALSS Findings	Analysis Tim MIC >= 64 >= 16	e: 14.13 hours	Antimicrobial fobrançcia zerofnacia Denyçeline Téxesçidee Microaphenicol	Patient Physician. Co States: MIC >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16	Reted: Oct 15, 2022 Final Final Reted: R R R R R R R R R R R R R R R R R R R	 24 Standard The Language 24 ST Finding: Contrast: Contrast:<td>n Analysia rettgeri MiC</td><td>rection Necrooned Fine: 18.03 load R R R R R R R R</td><td>Antimicrobial Ciperboacio Levoltoracio Minecycline Tigorycline Feodonycio Utine</td><td>T Physical C Status:</td><td>rises ID- 61 2518 effected: Oct 26, Final Interpretat R R R R S</td>	n Analysia rettgeri MiC	rection Necrooned Fine: 18.03 load R R R R R R R R	Antimicrobial Ciperboacio Levoltoracio Minecycline Tigorycline Feodonycio Utine	T Physical C Status:	rises ID- 61 2518 effected: Oct 26, Final Interpretat R R R R S
LES Findings antidover (c) antidover (c) ant	Analysis Tim MIC >= 64 >= 16	e: 14.13 hours	Antimicrobial fobrançcia zerofnacia Denyçeline Téxesçidee Microaphenicol	Patient Physician. Co States: MIC >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16	Reted: Oct 15, 2022 Final Final Reted: R R R R R R R R R R R R R R R R R R R	¹ Al De andial Pho Lee module ATE Finding Candidance (Control of Control Science) (Control of Control Science) (Control of Control Science) (Control of Control Control of Control of Control of Control of Control of Control Control of Control of Con	n Analysia Mice rettgeri Mice	Time: 11.83) hours	Antimicrobial Cprofosacia Levelosacia Minoycline Tegoyyline Feedonycia Utine Other	1 Physicia CO States: States: 	Final Rected: Oct 26, Final R. R. R. R. R. R. R. R. S. S.
LES Findings antideer. (c antideer. (c antideer. (c antideer. (c antideer. (c) antideer. (c) antidee	consistent with co cia rettgeri MIC >= 64 >= 64 >= 16 >= 32	Microbiology et 14.13 hours Interpretation R R R R R	Antimicrobial Ideamicin avofinacin Despyceline Telepised Weensphericol Statisti	Patient Physician. Co States: MIC >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16	Reted: Oct 15, 2022 Final Final Reted: R R R R R R R R R R R R R R R R R R R	¹ Al De andial Pho Lee module ATE Finding Candidance (Control of Control Science) (Control of Control Science) (Control of Control Science) (Control of Control Control of Control of Control of Control of Control of Control Control of Control of Con	n Analysia Mice rettgeri 232 22 24 24 23 22 24 24 23 22 24 24 23 22 24 24 22 24 24 22 24 24 24 24 24 24	Time: 11.83) hours	Antimicrobial Cprofosacia Levelosacia Minoycline Tegoyyline Feedonycia Utine Other	1 Physicia CO States: States: 	Final Rected: Oct 26, Final R. R. R. R. R. R. R. R. S. S.
ESFindings antifacer (c) antifacer (c) antif	Analysis Tim MIC >> 64 >> 16 >> 16	Microbiology e: 14.13 hours Interpretation R R R R R R R	Antimicrobial Ideamicin avofinacin Despyceline Telepised Weensphericol Statisti	Patient Physician. Co States: MIC >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16	Reted: Oct 15, 2022 Final Final Reted: R R R R R R R R R R R R R R R R R R R	Adds Charlenge Constant Adds Charlenge Constant Adds Charlenge Constant Constant Constant Constant Constant Constant Constant Constant Constant Constant	n Anatysis 7 MIC >= 16 32 >= 16 32 >= 16 32 >= 16	rection Anterconnect Fine: 18.03 hour R R R R R R R R R R R R	Astimicrobial Ciperfloracio Leventoucio Minocycline Teodonycio Urine Other Collario Collario	T Physica O Status: → 8 → 22 → 8 → 22 → 10 → 12 → 10	Final Rected: Oct 26, Final R. R. R. R. R. R. R. R. S. S.
ESFindings antifacer (c) antifacer (c) antif	Analysis Tim MIC >> 64 >> 16 >> 16	Microbiology e: 14.13 hours Interpretation R R R R R R R	Antimicrobial Ideamicin avofinacin Despyceline Telepised Weensphericol Statisti	Patient Physician. Co States: MIC >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16 >= 16	Reted: Oct 15, 2022 Final Final Reted: R R R R R R R R R R R R R R R R R R R	Adds Charlenge Constant Adds Charlenge Constant Adds Charlenge Constant Constant Constant Constant Constant Constant Constant Constant Constant Constant	intern with cor n Analysis 1 MIC	rection Anterconnect Fine: 18.03 hour R R R R R R R R R R R R	Astimicrobial Ciperfloracio Leventoucio Minocycline Teodonycio Urine Other Collario Collario	T Physica O Status: → 8 → 22 → 8 → 22 → 10 → 12 → 10	Final Rected: Oct 26, Final R. R. R. R. R. R. R. R. S. S.

Fig. 2: Identification of *Providencia rettgeri* with antibiotic sensitivity testing by vitek-2 showing multiple drug resistance and sensitive to fosfomycin

DISCUSSION

Providencia genera frequently causes a wound, respiratory and urinary tract infection by *Providencia stuartii*, *P. rettgeri*, *P. alcalifaciens*; gastrointestinal infection and diarrhea by *P. alcalifaciens*; bloodstream and poultry infection by *P. rettgeri*, *P. heimbachae* [1].

The significance and importance of *P. rettgeri* were first realized in south East Asian countries after the isolation of the same from surgical site infections as clusters in Nepal in 2014 [8]. *P. rettgeri* have been isolated as an etiological agent in 1986 (gastrointestinal illness), 2004 (traveler's diarrhea) and 20067 (ocular infection) [9-11]. In our case series, we isolated *P. rettgeri* from catheter urine samples causing CAUTI.

The clinical isolates showed resistance to antibiotics like amikacin (86%) and gentamicin (71%), as reported in a study carried out by Wie SH [12]. The extended spectrum beta-lactamase (ESBL) and New Delhi Metallo-beta lactamases-1 (NDM-1) producing strains of Providencia rettgeri have been reported in New Delhi, Eastern Europe, South America and Asia. The carbapenemase enzyme produced by NDM-1 strains of Providencia species is responsible for carbapenems resistance among *P. rettgeri* [13-15].

P. rettgeri and *P. stuartii* produce resistance to tobramycin and gentamicin commonly. However, both are susceptible or intermediate to gentamicin also. *P. rettgeri* showed earlier sensitivity to antibiotics like ciprofloxacin, cephalosporin, carbapenems and amoxicillinclavulanate. However, emerging resistance to ciprofloxacin has been reported among Providencia species with a shift in sensitivity pattern from 100% to 46% in a study carried out by Fass RJ *et al.* [16-18]. In our case series, we isolated multi-drug-resistant strains of *P. rettgeri* showed resistance to piperacillin-tazobactam, cefuroxime, ceftriaxone, cefepime, ertapenem, imipenem, meropenem, gentamicin, tobramycin, ciprofloxacin, tigecycline, amikacin, colistin and sensitive only to fosfomycin. *P. rettgeri* is known to be resistant to gentamicin and tobramycin but susceptible to Amikacin. All these findings together alarm us to follow routine antibiotic sensitivity testing for Providencia species.

The significance of *Providencia rettgeri* in association with catheterrelated bloodstream infections (CRBSI) and catheter-associated urinary tract infections (CAUTI) was not clear. Hence isolation of Providencia species twice from the clinical samples was considered for association with catheter infections. This association of CRBSI and CAUTI in Providencia species was reported by Wang TK *et al.* linking with bacterial urease production and biofilm formation among indwelling catheters used in peritonitis cases. The biofilm formation is responsible for inactive antimicrobial response in *Providencia rettgeri* by affecting penetration of and reducing the bioavailability *in vivo* [19, 20]. In our case series, we isolated multidrug-resistant strains of *P. rettgeri from catheterized patients*.

The proper selection of empirical antimicrobials, antibiotic sensitivity testing, avoiding misuse of antibiotics and implementing proper drug holidays and local antibiotic policy are considered appropriate combination protocols for managing emerging multi-drug-resistant nosocomial *Providencia rettgeri* strains. In our case, we fumigated the ICU after swabbing of the various sites in ICUs and cultured *Providencia rettgeri* and coagulase-negative Staphylococcus. Henceforth proper hand hygiene practices were strictly enrolled as per guidelines in wards and ICUs by the Hospital Infection Control Committee.

CONCLUSION

The differential diagnosis of Providencia species like *P. rettgeri* and *P. stuartii* among Enterobacteriaceae should be in our mind in the case of elderly with long-term indwelling catheters and empirical treatment failure. All clinical samples like urine, blood, sputum, pleural fluids, and BAL must also be screened for Providencia species in suspected presentations. The early diagnosis and management of UTI, CAUTI and other infections with specific antimicrobial therapy decides the patient's prognosis. As such, in association with obstruction, strictures and calculi, we must consider Providencia, Morganella and Proteus species as differential diagnoses and manage keenly with a combination of antimicrobials to save the patient at the earliest.

ACKNOWLEDGMENT

Nil

FUNDING

Nil

AUTORS CONTRIBUTIONS

First author contributions: Lab diagnosis and reporting

Second and corresponding author contributions: Lab Diagnosis, complete write-up, photos and editing.

Third author Contributions: Editing and compilation

Fourth author contributions: Supportive clinical diagnosis

CONFLICT OF INTERESTS

Declared none

REFERENCES

- O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000;13(4):534-46. doi: 10.1128/CMR.13.4.534, PMID 11023955.
- Armbruster CE, Smith SN, Yep A, Mobley HL. Increased incidence of urolithiasis and bacteremia during proteus mirabilis and providencia stuartii coinfection due to synergistic induction of urease activity. J Infect Dis. 2014;209(10):1524-32. doi: 10.1093/infdis/jit663, PMID 24280366.
- 3. Hawkey PM. Providencia stuartii: a review of a multiply antibiotic-resistant bacterium. J Antimicrob Chemother. 1984;13(3):209-26. doi: 10.1093/jac/13.3.209, PMID 6373713.
- Warren JW. Providencia stuartii: a common cause of antibioticresistant bacteriuria in patients with long-term indwelling catheters. Rev Infect Dis. 1986;8(1):61-7. doi: 10.1093/clinids/8.1.61, PMID 3081988.
- Jones BD, Mobley HL. Genetic and biochemical diversity of ureases of proteus, Providencia, and Morganella species isolated from urinary tract infection. Infect Immun. 1987;55(9):2198-203. doi: 10.1128/iai.55.9.2198-2203.1987, PMID 3623698.
- Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clin Infect Dis. 2001;33(9):1567-72. doi: 10.1086/323130, PMID 11577378.
- Al-Jubouri MA, Vardhan MS. A case of purple urine bag syndrome associated with Providencia rettgeri. J Clin Pathol. 2001;54(5):412. doi: 10.1136/jcp.54.5.412-a, PMID 11328846.
- Tada T, Miyoshi Akiyama T, Dahal RK, Sah MK, Ohara H, Shimada K. NDM-1 Metallo-β-lactamase and ArmA 16S rRNA methylase producing providencia rettgeri clinical isolates in Nepal. BMC Infect Dis. 2014;14:56. doi: 10.1186/1471-2334-14-56, PMID 24484534.
- Müller HE. Occurrence and pathogenic role of organelleproteus-Providencia group bacteria in human feces. J Clin Microbiol. 1986;23(2):404-5. doi: 10.1128/jcm.23.2.404-405.1986, PMID 3517057.
- Yoh M, Matsuyama J, Ohnishi M, Takagi K, Miyagi H, Mori K. Importance of Providencia species as a major cause of travellers' diarrhoea. J Med Microbiol. 2005;54(11):1077-82. doi: 10.1099/jmm.0.45846-0, PMID 16192440.
- Koreishi AF, Schechter BA, Karp CL. Ocular infections caused by *Providencia rettgeri*. Ophthalmology. 2006;113(8):1463-66. doi: 10.1016/j.ophtha.2006.03.047, PMID 16797710.
- Wie SH. Clinical significance of Providencia bacteremia or bacteriuria. Korean J Intern Med. 2015;30(2):167-9. doi: 10.3904/kjim.2015.30.2.167, PMID 25750557.
- Marchandin H, Carriere C, Sirot D, Pierre HJ, Darbas H. TEM-24 produced by four different species of Enterobacteriaceae, including providencia rettgeri, in a single patient. Antimicrob Agents Chemother. 1999;43(8):2069-73. doi: 10.1128/AAC.43.8.2069, PMID 10428940.
- 14. Cornaglia G, Frugoni S, Mazzariol A, Piacentini E, Berlusconi A, Fontana R. Activities of oral antibiotics on providencia strains isolated from institutionalized elderly patients with urinary tract infections. Antimicrob Agents Chemother. 1995;39(12):2819-21. doi: 10.1128/AAC.39.12.2819, PMID 8593030.
- Barrios H, Garza Ramos U, Reyna Flores F, Sanchez Perez A, Rojas Moreno T, Garza Gonzalez E. Isolation of carbapenem-resistant NDM-1-positive providencia rettgeri in mexico. J Antimicrob Chemother. 2013;68(8):1934-6. doi: 10.1093/jac/dkt124. PMID 23620464.
- 16. Usharani P. Incidence and outcome of multidrug-resistant aerobic gram-negative bacteria causing various clinical infections. Asian J Pharm Clin Res. 2021. Dec 15;2:123-6. doi: 10.22159/ajpcr.2022.v15i2.43436.
- 17. Mehta A, Kr Diwakar M. Characterization and antimicrobial susceptibility profile of non-lactose fermenting gram-negative

bacterial isolates in a tertiary care teaching hospital of central India. Asian J Pharm Clin Res. 2021. Oct;14(10):41-7. doi: 10.22159/ajpcr.2021.v14i10.42822.

- Fass RJ, Barnishan J, Ayers LW. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital. J Antimicrob Chemother. 1995;36(2):343-53. doi: 10.1093/jac/36.2.343, PMID 8522464.
- Blaser MJ, Dolin R, Mandell GL, Douglas RG1, Bennett JE, Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier/Saunders; 2015.
- Wang TK, Ahn Y, Dunlop J. *Providencia rettgeri* peritonitis in a patient on peritoneal dialysis with perforated appendicitis. Perit Dial Int. 2014;34(5):569-70. doi: 10.1177/089686081403400501, PMID 25075004.